Lactose-N-fucopentose VI—the core breast milk oligosaccharide of health productsCAS: 145876-86-4

Lacto-N-fucopentaose VI (LNFP VI) is an important member of the human milk oligosaccharides (HMOs) family and is known as the "smart sugar source in early life." It is not only a key bioactive ingredient naturally found in breast milk, but also an indispensable functional raw material in the fields of modern nutrition, infant health food and high-end biomedical research.

Chemical Information

Chemical name: Lactose-N-fucopentose VI

Common name: LNFP VI

English name: Lacto-N-fucopentaose VI

Chemical formula: C₃₂H₅₅NO₂₅

Molecular weight: 853.77 g/mol

CAS number: 145876-86-4

Structural features

Lactose-N-fucopentose VI is a fucosylated human milk oligosaccharide, and its structure has the following unique features:

Precise polysaccharide architecture: LNFP VI is extended by a lactose core, connected to N-acetylglucosamine through β-1,3 bonds, and further conjugated to fucosyl groups. Its structure is: Galβ1-3GlcNAcβ1-3Galβ1-4Glc (lactose-N-tetrasaccharide skeleton), and fucose is connected with α1-3 bonds at specific positions.

Close connection between structure and function: The precise arrangement of sugar chains enables it to be specifically recognized and utilized by intestinal flora (such as bifidobacteria). It can also serve as a similar "bait receptor" to block pathogen adhesion and play an important biological barrier function.

High degree of stereospecificity: The configuration and connection sequence of its glycosidic bonds determine its interaction with microorganisms, immune cell surface lectins and host receptors, and is the structural basis for its probiotic and immunomodulatory effects.

Main applications and advantages

1. Core functional components of infant nutrition and high-end formula foods

Simulated breast milk, precise nutrition:

Breast milk oligosaccharides are the third largest solid component in breast milk and have a profound impact on intestinal health, immune development and cognitive development of infants and young children. LNFP VI, as one of the key fucosylated oligosaccharides, can:

Promote probiotic colonization: Selectively stimulate the growth of beneficial bacteria such as Bifidobacterium and establish a healthy intestinal microecology.

Inhibit pathogen infection: By competitively binding to receptors on the surface of intestinal epithelial cells, it prevents the adhesion of pathogenic bacteria (such as Escherichia coli and Salmonella) and reduces the risk of infection.

Regulates immune response: affects lymphocyte differentiation and cytokine secretion, helps the balanced development of the immune system of infants and young children, and reduces the risk of allergies and inflammation.

LNFP VI provides scientific and credible raw material guarantee for the development of "breast-milked" high-end infant formula, baby food for special medical purposes and infant prebiotic supplements.

2. Rising star of adult health food and functional ingredients

Gut Health and Metabolic Regulation:

In recent years, the application of HMOs has been extended to the field of adult nutrition:

Improve intestinal barrier function: LNFP VI can enhance the integrity of the mucus layer and relieve symptoms of leaky gut. It is suitable for dietary support for people with intestinal dysfunction, inflammatory bowel disease, etc.

Dual regulation of metabolism and immunity: By regulating the structure of intestinal flora, it indirectly affects host metabolism and systemic low-grade inflammation, providing a new dietary strategy for the prevention of metabolic syndrome, obesity and diabetes.

High-end functional food additives: suitable for prebiotic mixtures, intestinal health supplements, special medical foods and oral nutritional support products.

3. An important tool for biomedical research and drug development

Glycobiology and Microbiome Research:

Probe for mechanism research: LNFP VI is an ideal molecular tool for studying host-microbe interactions, sugar-receptor recognition, and immune regulatory signaling pathways.

Development of new anti-infection strategies: Using it as a template, pathogen adhesion inhibitors can be designed and new antibacterial and antiviral carbohydrate drugs or protective agents can be developed.

Drug delivery and targeting carriers: Using its specific binding ability, drug delivery systems targeting intestinal or immune cells can be constructed.

4. In vitro diagnostics and biomarker potential

Disease Association and Detection:

Changes in the spectrum of specific HMOs in breast milk or serum are related to maternal health status, infant and young child development stages, and even certain diseases. As an important component, LNFP VI can be used for:

Breast milk quality assessment: used as a standard for breast milk component analysis to evaluate nutrition and immune function.

Disease biomarker development: Study their association with intestinal diseases, metabolic diseases and even neurodevelopmental abnormalities, and develop new diagnostic indicators.

Conclusion

Lactose-N-fucopentose VI is not just an oligosaccharide, it is a natural bridge connecting early life nutrition, intestinal microecology and immune health. From creating the next generation of "breast-milk grade" infant formula, to opening up a new era of adult intestinal health, from deciphering the host-microbe dialogue mechanism, to developing new carbohydrate biologics, its value is being continuously explored and recognized.

The above information is provided by the editor of KASONS and is for scientific research only.